APM (Aptorum Group) Debt-to-Asset : 0.19 (As of Jun. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Aptorum Group Debt-to-Asset?

Aptorum Group's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was $0.09 Mil. Aptorum Group's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was $3.21 Mil. Aptorum Group's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2024 was $17.71 Mil. Aptorum Group's debt to asset for the quarter that ended in Jun. 2024 was 0.19.

Aptorum Group Debt-to-Asset Historical Data

The historical data trend for Aptorum Group's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aptorum Group Debt-to-Asset Chart

Aptorum Group Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.27

0.06

0.01

0.33

0.16

Aptorum Group Semi-Annual Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Debt-to-Asset	Get a 7-Day Free Trial									0.15	0.33	0.04	0.16	0.19

Competitive Comparison of Aptorum Group's Debt-to-Asset

For the Biotechnology subindustry, Aptorum Group's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aptorum Group's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aptorum Group's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Aptorum Group's Debt-to-Asset falls into.

Save Embed

;

Save Embed

;

Aptorum Group Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Aptorum Group's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.125	+	3.158)	/	20.64
	=	0.16

Aptorum Group's Debt-to-Asset for the quarter that ended in Jun. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.089	+	3.211)	/	17.705
	=	0.19

Aptorum Group (NAS:APM) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Aptorum Group Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Aptorum Group's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Aptorum Group Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aptorum Group Ltd (NAS:APM) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

17 Hanover Square, London, GBR, W1S 1BN

Website

https://www.aptorumgroup.com

Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.